Table 6.

Comparison of Predicted Class Member Characteristics

Characteristic	Class 1 (n = 45)	Class 2 (n = 48)	Class 3 (n = 10)	P Valuea
Demographics
Age, y	36	36	36	.99
Sex, % female	43	54	78b	.1
Clinical measures
ppFEV1	71	64	85b	.02
Mild, %	52	43	70	.4
Moderate, %	36	43	30
Severe, %	11	15	0
absFEV1, L	2.72	2.22c	2.51	.08
ppFVC	88	80b	99	.01
absFVC, L	3.94	3.35c	3.88	.04
Diagnosis of GERD, %	41	42	44	.98
Diagnosis of CFRD, %	25	33	22	.6
BMI	23	23	24	.7
Treatment characteristics
Treatment complexity score	22	23	16c	.01
Total treatment time, min/d	91	104	42c	.04
Physiotherapy time, min/d	38	42	17b	.09
Inhaled medicines time, min/d	45	46	19b	.1
No. chronic treatments	13	14	9c	.02
Prescribed CFTR modulator, %	70	60	67	.6
Prescribed elexacaftor/tezacaftor/ivacaftor, %	34	29	44	.7
Received IV antibiotics in last year, %	39	35	22	.6
Number of IV antibiotic courses in last yeard	2.5	2.9	1.5	.6
HRQoL and treatment burden measures
EQ-5D Index score	0.80	0.72c	0.88b	.02
EQ-5D VAS score	75	74	80	.6
CFQ-R treatment burden domain score	54	50	74c	.007
CFQoL treatment burden domain score	63	63	76	.3
MTBQ index score (reversed)	80	81	90c	.09

absFEV₁ = absolute FEV₁; absFVC = absolute FVC; CFQ-R = Cystic Fibrosis Questionnaire-Revised; CFQoL = cystic fibrosis-related quality of life; CFRD = cystic fibrosis-related diabetes; CFTR = cystic fibrosis transmembrane conductance regulator; EQ-5D = EuroQol-5 Dimension; GERD = gastroesophageal reflux disease; HRQoL = health-related quality of life; MTBQ = Multimorbidity Treatment Burden Questionnaire; ppFEV₁ = FEV₁ % predicted; ppFVC = FVC % predicted.

^aOne-way analysis of variance tests used for continuous variables, Pearson’s χ² used for categorical variables.

^bP < .1, t-test comparisons against class 1.

^cP < .05, t-test comparisons against class 1.

^dFor those who received at least one IV antibiotic course.